

Applicants : Daniel J. Capon, Jeannette M. Whitcomb and
Neil T. Parkin
Serial No. : 09/126,559
Filed : July 30, 1998
Page 2

RECEIVED
JUL 18 2000
TECHNICAL ROOM

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

On page 42, line 7, after "cells", delete "is this" and replace with --this is--.

On page 42, line 12, after "HCV," delete --a--.

On Page 42, line 18, after "HCMV," delete --a--.

IN THE CLAIMS:

Please amend claims 1, 4, 8, 37, and 40 under the provisions of 37 C.F.R. §1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

1. (Amended) A method for determining susceptibility for an HCV anti-viral drug comprising:
- (a) introducing a resistance test vector comprising a patient-derived segment which comprises a hepatitis C virus (HCV) gene and an indicator gene into a host cell;
 - (b) culturing the host cell from (a);
 - (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and
 - (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the HCV anti-viral drug,

INS
E1

CT